The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Majedie Investments Net Assets Fall As It Hikes Payout, Redeems Debt

Wed, 05th Dec 2018 11:56

LONDON (Alliance News) - Majedie Investments PLC on Wednesday reported a decrease in net asset value over its financial year due to making higher dividend payouts and redeeming debentures, as its biggest fund underperformed its benchmark.

At September 30, the investment trust's NAV per share with debt at par value was 334.3 pence, down 2.1.% compared to 341.6p last year. With debt at fair value, Majedie's NAV per share decreased slightly in the same period to 326.2p at September 30 from 327.8p the year before.

Majedie's NAV total return at par value was 0.9% and at fair value was 2.7%. The trust did, however, note the redemption of its 2020 9.5% debentures in December 2017, which diluted the NAV at par value by 1.6% and by 0.6% at fair value.

The trust said it redeemed the debenture in order to reduce its gearing "as markets were at all time highs". Majedie's gearing reduced to 10% at September 30 from 17% a year before.

A gearing ratio is a measure of financial leverage, meaning the degree to which a firm's operations are funded by equity capital versus creditor financing. A higher gearing ratio indicates a higher degree of leverage.

The trust's net assets decreased 2.1% to GBP178.6 million from GBP182.5 million last year.

Majedie's net assets were hurt by its increased dividend payout and by a premium paid on redeeming the 2020 debentures.

Majedie upped its total dividend payment for the year by 13% to 11.00 from the 9.75p last year.

The FTSE All Share Index rose by 5.9% in the period and the MSCI World Index gained 12.9%. Majedie has no overall benchmark; instead its funds have their own separate benchmarks.

The biggest contributors to the trust's net assets were funds run by its manager Majedie Asset Management. Majedie Investments holds a 17% stake in Majedie Asset Management.

Majedie Investments noted the Majedie Asset Management UK Equity Segregated portfolio, which represents 29% of Majedie Investments total assets, underperformed it benchmark.

The fund returned 3.0% net of fees to Majedie Investments, which is a 2.9% underperformance against its benchmark - the FTSE All Share Index. The biggest detractors from the fund were overweight positions in general retail, gold mining and fixed line telecoms. Specifically, overweight positions in Barrick Gold Corp and Saga PLC hurt the fund's performance, as was not holding AstraZeneca PLC, Majedie said.

Chief Executive Officer William Barlow said: "Against a background of rising political concerns notably Brexit in the UK, but also in the US and Europe and rising economic concerns as quantitative easing turns to quantitative tightening, interest rate rises due to inflationary concerns, early signs of leading economic indicators rolling over and the Chinese economy slowing; the company's positioning has been defensive throughout the year. In retrospect this was too early but the recent market turbulence suggests the defensive positioning will be more appropriate in the current year."

Shares in Majedie Investments were down 1.7% Wednesday at 264.50 pence each.

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.